Skip to search formSkip to main contentSkip to account menu

ILX 651

Known as: ILX-651, ILX651 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tasidotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite
The pharmacokinetics of tasidotin (ILX651), a depsipeptide currently in phase II for the treatment of advanced solid tumors, and… 
Highly Cited
2006
Highly Cited
2006
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of… 
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651… 
2005
2005
A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of the dolastatin-15 analogue… 
2005
2005
ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience
7556 Background: ILX65, a synthetic pentapeptide derivative of dolastatin-15, has a unique mechanism of action. At low… 
2004
2004
Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma
7530 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers… 
2004
2004
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors.
3068 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers… 
2004
2004
Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma.
7530 Background: SYN-D is a pentapeptide with a unique mechanism of action that potentially differs from microtubule stabilizers… 
2004
2004
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
2082 Background: Synthadotin (ILX651) is a pentapeptide with a unique mechanism of action that potentially differs from that of… 
2004
2004
In vitro metabolism and interaction studies with celecoxib and lovastatin.
2122 There is considerable interest in the development of COX-2 (cyclooxygenase-2) and HMG-CoA (3-hydroxy-3-methylglutaryl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)